Immunotherapy with ipilimumab plus nivolumab in a stage IV melanoma patient during pregnancy
- 25 October 2018
- journal article
- letter
- Published by Elsevier BV in European Journal Of Cancer
- Vol. 104, 239-242
- https://doi.org/10.1016/j.ejca.2018.09.008
Abstract
No abstract availableThis publication has 12 references indexed in Scilit:
- An Evaluation of the Impact of PD‐1 Pathway Blockade on Reproductive Safety of Therapeutic PD‐1 InhibitorsBirth Defects Research Part B: Developmental and Reproductive Toxicology, 2016
- Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysisBMC Medicine, 2015
- New systemic agents in dermatology with respect to fertility, pregnancy, and lactationJDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2015
- Treatment of Metastatic Malignant Melanoma With Vemurafenib During PregnancyJournal of Clinical Oncology, 2013
- Concordance of preclinical and clinical pharmacology and toxicology of therapeutic monoclonal antibodies and fusion proteins: cell surface targetsBritish Journal of Pharmacology, 2012
- Pregnancy outcomes after kidney transplantation-immunosuppressive therapy comparisonThe Journal of Maternal-Fetal & Neonatal Medicine, 2011
- Cancer and Pregnancy: Parallels in Growth, Invasion, and Immune Modulation and Implications for Cancer Therapeutic AgentsMayo Clinic Proceedings, 2009
- Hormones, nevi, and melanoma: An approach to the patientJournal of the American Academy of Dermatology, 2007
- Metastatic Melanoma in Pregnancy: Risk of Transplacental Metastases in the InfantJournal of Clinical Oncology, 2003
- Applicability of reference values for the determination of serum S100 protein as a marker of malignant melanoma in childrenBritish Journal of Dermatology, 2002